Fig. 1

Age-at-diagnosis of AD and age-at-baseline by BCHE-K carrier status in APOE4 carriers, homozygotes, and heterozygotes. A Age-at-diagnosis of AD in APOE4 carriers by BCHE-K carrier status. B Age-at-diagnosis of AD in APOE4 homozygotes and heterozygotes by BCHE-K carrier status. C Age-at-baseline of study in APOE4 carriers by BCHE-K carrier status. D Age-at-baseline of study in APOE4 homozygotes and heterozygotes by BCHE-K carrier status. * P < .001, ANOVA; P = .001, ANCOVA with BCHE-K carrier status and sex as factors and baseline MMSE total score as covariate for mean age-at-diagnosis of AD. **P = .013, ANOVA; P = .019, ANCOVA with APOE4 homozygotes and heterozygotes by BCHE-K carrier status and sex as factors and baseline MMSE total score as covariate for mean age-at-diagnosis of AD. † P = .001, ANOVA; P = .002, ANCOVA with BCHE-K carrier status and sex as factors and baseline MMSE total score as covariate for mean age-at-study-baseline. †† P = .015, ANOVA; P = .025, ANCOVA with APOE4 homozygotes and heterozygotes by BCHE-K carrier status and sex as factors and baseline MMSE total score as covariate for mean age-at-study-baseline